Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picankibart in Plaque Psoriasis Patients With Inadequate Response to IL-17 Monoclonal Antibody Therapy
NCT06945107Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of picankibart in plaque psoriasis (2 arms), sponsored by Innovent Biologics. Primary endpoint: Static Physician's Global Assessment score of clear (0) or almost clear (1) at 16 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06945107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945107.